Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Joseph Aspirin Is First J&J/McNeil Divestiture From 2010 OTC Recalls

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson unloads St. Joseph Aspirin, an OTC brand that suffered a significant dip in sales following a 2010 recall due to contaminated packaging.

You may also be interested in...



J&J’s Mylanta, Mylicon Lines Return Via ‘Fixed-Term’ License With Infirst

Unlike other OTC deals J&J made since McNeil Consumer Healthcare’s quality-control problems led to widespread recalls and a consent decree with FDA, the firm is not divesting the digestive health lines. Infirst will manufacture and market the products in the U.S. for an undisclosed period before the brands return to McNeil.

J&J’s Mylanta, Mylicon Lines Return Via ‘Fixed-Term’ License With Infirst

Unlike other OTC deals J&J made since McNeil Consumer Healthcare’s quality-control problems led to widespread recalls and a consent decree with FDA, the firm is not divesting the digestive health lines. Infirst will manufacture and market the products in the U.S. for an undisclosed period before the brands return to McNeil.

J&J Cites Neutrogena Among 20 Product Launches Planned For 2015

CEO Alex Gorsky says “20 key product launches” are targeted for 2015, including extensions of the Neutrogena Hydro Boost skin-care and Listerine Healthy White mouthwash lines. Skin care propelled U.S. growth of 2.5% in J&J’s consumer-health business during the fourth quarter, the firm reported.

Related Content

Topics

UsernamePublicRestriction

Register

PS104788

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel